nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoprolol—SLC22A2—nephron—nephrolithiasis	0.0612	0.36	CbGeAlD
Metoprolol—Conduction disorder—Hydrochlorothiazide—nephrolithiasis	0.0556	0.0814	CcSEcCtD
Metoprolol—Obstructive airways disorder—Hydrochlorothiazide—nephrolithiasis	0.0513	0.0752	CcSEcCtD
Metoprolol—Atrioventricular block complete—Hydrochlorothiazide—nephrolithiasis	0.0333	0.0488	CcSEcCtD
Metoprolol—CYP2C19—urine—nephrolithiasis	0.0267	0.157	CbGeAlD
Metoprolol—Sexual dysfunction—Hydrochlorothiazide—nephrolithiasis	0.0208	0.0304	CcSEcCtD
Metoprolol—Sleep disturbance—Hydrochlorothiazide—nephrolithiasis	0.0208	0.0304	CcSEcCtD
Metoprolol—SLC22A2—Organic cation/anion/zwitterion transport—SLC22A12—nephrolithiasis	0.0203	0.138	CbGpPWpGaD
Metoprolol—Respiratory distress—Hydrochlorothiazide—nephrolithiasis	0.0183	0.0269	CcSEcCtD
Metoprolol—Heartburn—Hydrochlorothiazide—nephrolithiasis	0.0169	0.0248	CcSEcCtD
Metoprolol—CYP2D6—urine—nephrolithiasis	0.0155	0.0914	CbGeAlD
Metoprolol—Memory impairment—Hydrochlorothiazide—nephrolithiasis	0.0148	0.0217	CcSEcCtD
Metoprolol—ADRB1—Endothelin Pathways—ADCY10—nephrolithiasis	0.0146	0.0993	CbGpPWpGaD
Metoprolol—SLC22A2—nephron tubule—nephrolithiasis	0.0132	0.0777	CbGeAlD
Metoprolol—SLC22A2—renal system—nephrolithiasis	0.012	0.0706	CbGeAlD
Metoprolol—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.0118	0.0173	CcSEcCtD
Metoprolol—Ventricular tachycardia—Hydrochlorothiazide—nephrolithiasis	0.0116	0.0171	CcSEcCtD
Metoprolol—SLC22A2—kidney—nephrolithiasis	0.0116	0.0683	CbGeAlD
Metoprolol—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.0113	0.0166	CcSEcCtD
Metoprolol—SLC22A2—cortex of kidney—nephrolithiasis	0.0113	0.0665	CbGeAlD
Metoprolol—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.00977	0.0143	CcSEcCtD
Metoprolol—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00972	0.0142	CcSEcCtD
Metoprolol—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.00963	0.0141	CcSEcCtD
Metoprolol—Libido decreased—Hydrochlorothiazide—nephrolithiasis	0.00912	0.0134	CcSEcCtD
Metoprolol—Hot flush—Hydrochlorothiazide—nephrolithiasis	0.00904	0.0132	CcSEcCtD
Metoprolol—Menopausal symptoms—Hydrochlorothiazide—nephrolithiasis	0.00896	0.0131	CcSEcCtD
Metoprolol—Visual disturbance—Hydrochlorothiazide—nephrolithiasis	0.00892	0.0131	CcSEcCtD
Metoprolol—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.0087	0.0127	CcSEcCtD
Metoprolol—Disturbance in sexual arousal—Hydrochlorothiazide—nephrolithiasis	0.00839	0.0123	CcSEcCtD
Metoprolol—Affect lability—Hydrochlorothiazide—nephrolithiasis	0.00832	0.0122	CcSEcCtD
Metoprolol—Mood swings—Hydrochlorothiazide—nephrolithiasis	0.00801	0.0117	CcSEcCtD
Metoprolol—Liver function test abnormal—Hydrochlorothiazide—nephrolithiasis	0.0078	0.0114	CcSEcCtD
Metoprolol—Orthostatic hypotension—Hydrochlorothiazide—nephrolithiasis	0.00772	0.0113	CcSEcCtD
Metoprolol—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.00772	0.0113	CcSEcCtD
Metoprolol—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.00764	0.0112	CcSEcCtD
Metoprolol—Cramp muscle—Hydrochlorothiazide—nephrolithiasis	0.00761	0.0112	CcSEcCtD
Metoprolol—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.00712	0.0104	CcSEcCtD
Metoprolol—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.00673	0.00986	CcSEcCtD
Metoprolol—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00667	0.00977	CcSEcCtD
Metoprolol—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.00665	0.00974	CcSEcCtD
Metoprolol—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00655	0.0096	CcSEcCtD
Metoprolol—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.00635	0.0093	CcSEcCtD
Metoprolol—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00633	0.00928	CcSEcCtD
Metoprolol—Sweating—Hydrochlorothiazide—nephrolithiasis	0.00625	0.00915	CcSEcCtD
Metoprolol—Agranulocytosis—Hydrochlorothiazide—nephrolithiasis	0.00608	0.00891	CcSEcCtD
Metoprolol—ADRB1—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00608	0.0412	CbGpPWpGaD
Metoprolol—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00595	0.00872	CcSEcCtD
Metoprolol—ADRB2—Monoamine GPCRs—CHRM3—nephrolithiasis	0.00595	0.0403	CbGpPWpGaD
Metoprolol—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00586	0.00859	CcSEcCtD
Metoprolol—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.00585	0.00857	CcSEcCtD
Metoprolol—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00576	0.00844	CcSEcCtD
Metoprolol—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00564	0.00826	CcSEcCtD
Metoprolol—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00545	0.00799	CcSEcCtD
Metoprolol—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00522	0.00766	CcSEcCtD
Metoprolol—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00517	0.00757	CcSEcCtD
Metoprolol—ADRB1—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.00511	0.0346	CbGpPWpGaD
Metoprolol—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00502	0.00735	CcSEcCtD
Metoprolol—ADRB2—Amine ligand-binding receptors—CHRM3—nephrolithiasis	0.005	0.0339	CbGpPWpGaD
Metoprolol—Tension—Hydrochlorothiazide—nephrolithiasis	0.005	0.00732	CcSEcCtD
Metoprolol—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00499	0.0073	CcSEcCtD
Metoprolol—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00494	0.00725	CcSEcCtD
Metoprolol—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00489	0.00717	CcSEcCtD
Metoprolol—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.0048	0.00703	CcSEcCtD
Metoprolol—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00457	0.0067	CcSEcCtD
Metoprolol—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00457	0.00669	CcSEcCtD
Metoprolol—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.00456	0.00668	CcSEcCtD
Metoprolol—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.0045	0.00659	CcSEcCtD
Metoprolol—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00447	0.00656	CcSEcCtD
Metoprolol—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00433	0.00635	CcSEcCtD
Metoprolol—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00433	0.00635	CcSEcCtD
Metoprolol—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00432	0.00633	CcSEcCtD
Metoprolol—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00424	0.00621	CcSEcCtD
Metoprolol—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00419	0.00614	CcSEcCtD
Metoprolol—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00415	0.00609	CcSEcCtD
Metoprolol—Shock—Hydrochlorothiazide—nephrolithiasis	0.00409	0.00599	CcSEcCtD
Metoprolol—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A12—nephrolithiasis	0.00408	0.0276	CbGpPWpGaD
Metoprolol—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00407	0.00596	CcSEcCtD
Metoprolol—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00405	0.00594	CcSEcCtD
Metoprolol—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00402	0.00589	CcSEcCtD
Metoprolol—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.00388	0.00569	CcSEcCtD
Metoprolol—CYP2D6—renal system—nephrolithiasis	0.0038	0.0224	CbGeAlD
Metoprolol—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A9—nephrolithiasis	0.00379	0.0257	CbGpPWpGaD
Metoprolol—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00379	0.00555	CcSEcCtD
Metoprolol—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00376	0.00551	CcSEcCtD
Metoprolol—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00373	0.00547	CcSEcCtD
Metoprolol—ADRB1—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00373	0.0253	CbGpPWpGaD
Metoprolol—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.0037	0.00543	CcSEcCtD
Metoprolol—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00369	0.00541	CcSEcCtD
Metoprolol—CYP2D6—kidney—nephrolithiasis	0.00368	0.0216	CbGeAlD
Metoprolol—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00366	0.00536	CcSEcCtD
Metoprolol—ADRB2—Calcium Regulation in the Cardiac Cell—RGS14—nephrolithiasis	0.00365	0.0247	CbGpPWpGaD
Metoprolol—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00358	0.00525	CcSEcCtD
Metoprolol—Pain—Hydrochlorothiazide—nephrolithiasis	0.00355	0.00521	CcSEcCtD
Metoprolol—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00355	0.00521	CcSEcCtD
Metoprolol—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00342	0.00502	CcSEcCtD
Metoprolol—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.0034	0.00498	CcSEcCtD
Metoprolol—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.0033	0.00484	CcSEcCtD
Metoprolol—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00328	0.00481	CcSEcCtD
Metoprolol—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00328	0.00481	CcSEcCtD
Metoprolol—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00306	0.00449	CcSEcCtD
Metoprolol—ABCB1—nephron tubule—nephrolithiasis	0.00301	0.0177	CbGeAlD
Metoprolol—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00298	0.00437	CcSEcCtD
Metoprolol—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00294	0.00431	CcSEcCtD
Metoprolol—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00284	0.00417	CcSEcCtD
Metoprolol—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00275	0.00403	CcSEcCtD
Metoprolol—ABCB1—renal system—nephrolithiasis	0.00274	0.0161	CbGeAlD
Metoprolol—SLC22A2—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.00267	0.0181	CbGpPWpGaD
Metoprolol—ABCB1—kidney—nephrolithiasis	0.00265	0.0156	CbGeAlD
Metoprolol—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00264	0.00387	CcSEcCtD
Metoprolol—ADRB2—GPCRs, Other—CHRM3—nephrolithiasis	0.00264	0.0179	CbGpPWpGaD
Metoprolol—Rash—Hydrochlorothiazide—nephrolithiasis	0.00262	0.00384	CcSEcCtD
Metoprolol—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00262	0.00384	CcSEcCtD
Metoprolol—Headache—Hydrochlorothiazide—nephrolithiasis	0.0026	0.00381	CcSEcCtD
Metoprolol—ABCB1—cortex of kidney—nephrolithiasis	0.00258	0.0151	CbGeAlD
Metoprolol—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00247	0.00362	CcSEcCtD
Metoprolol—SLC22A2—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.00244	0.0166	CbGpPWpGaD
Metoprolol—SLC22A2—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.00244	0.0166	CbGpPWpGaD
Metoprolol—ADRB1—G alpha (s) signalling events—PTH—nephrolithiasis	0.00193	0.0131	CbGpPWpGaD
Metoprolol—ADRB2—G alpha (s) signalling events—PTH—nephrolithiasis	0.00189	0.0128	CbGpPWpGaD
Metoprolol—SLC22A2—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.00185	0.0126	CbGpPWpGaD
Metoprolol—SLC22A2—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.00185	0.0126	CbGpPWpGaD
Metoprolol—ADRB1—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00182	0.0123	CbGpPWpGaD
Metoprolol—ADRB2—Calcium Regulation in the Cardiac Cell—CHRM3—nephrolithiasis	0.00178	0.0121	CbGpPWpGaD
Metoprolol—SLC22A2—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.00172	0.0117	CbGpPWpGaD
Metoprolol—SLC22A2—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.00172	0.0117	CbGpPWpGaD
Metoprolol—SLC22A2—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.00153	0.0104	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.00152	0.0103	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.00152	0.0103	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.00136	0.00921	CbGpPWpGaD
Metoprolol—CYP2C19—Biological oxidations—SLC26A1—nephrolithiasis	0.00134	0.00909	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00124	0.00842	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00124	0.00842	CbGpPWpGaD
Metoprolol—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.00123	0.00836	CbGpPWpGaD
Metoprolol—ADRB1—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00117	0.00795	CbGpPWpGaD
Metoprolol—ADRB2—GPCRs, Class A Rhodopsin-like—CHRM3—nephrolithiasis	0.00115	0.00778	CbGpPWpGaD
Metoprolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.00101	0.00681	CbGpPWpGaD
Metoprolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CHRM3—nephrolithiasis	0.000983	0.00667	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000941	0.00638	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000941	0.00638	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—RGS14—nephrolithiasis	0.000886	0.00601	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000875	0.00593	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000875	0.00593	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—RGS14—nephrolithiasis	0.000866	0.00587	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000832	0.00564	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000832	0.00564	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—RGS14—nephrolithiasis	0.000804	0.00545	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—RGS14—nephrolithiasis	0.000787	0.00533	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.00078	0.00529	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.00078	0.00529	CbGpPWpGaD
Metoprolol—ADRB1—GPCR ligand binding—CHRM3—nephrolithiasis	0.000765	0.00519	CbGpPWpGaD
Metoprolol—ADRB2—GPCR ligand binding—CHRM3—nephrolithiasis	0.000749	0.00508	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000742	0.00503	CbGpPWpGaD
Metoprolol—ADRB1—GPCR ligand binding—PTH—nephrolithiasis	0.0007	0.00475	CbGpPWpGaD
Metoprolol—ADRB2—GPCR ligand binding—PTH—nephrolithiasis	0.000685	0.00464	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000678	0.0046	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000678	0.0046	CbGpPWpGaD
Metoprolol—SLC22A2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000623	0.00423	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—DGKH—nephrolithiasis	0.000598	0.00406	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—DGKH—nephrolithiasis	0.000585	0.00397	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ADCY10—nephrolithiasis	0.000559	0.00379	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ADCY10—nephrolithiasis	0.000547	0.00371	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—DGKH—nephrolithiasis	0.000543	0.00368	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—GRHPR—nephrolithiasis	0.000541	0.00367	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—DGKH—nephrolithiasis	0.000531	0.0036	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000514	0.00349	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000514	0.00349	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—AGXT—nephrolithiasis	0.000482	0.00327	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000478	0.00324	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000478	0.00324	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—RGS14—nephrolithiasis	0.000475	0.00322	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—RGS14—nephrolithiasis	0.000465	0.00315	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000433	0.00293	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000426	0.00289	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000426	0.00289	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—CHRM3—nephrolithiasis	0.000423	0.00287	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—APRT—nephrolithiasis	0.00041	0.00278	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—SLC26A1—nephrolithiasis	0.00041	0.00278	CbGpPWpGaD
Metoprolol—ADRB1—GPCR downstream signaling—PTH—nephrolithiasis	0.000396	0.00268	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—CHRM3—nephrolithiasis	0.000393	0.00266	CbGpPWpGaD
Metoprolol—ADRB2—GPCR downstream signaling—PTH—nephrolithiasis	0.000387	0.00262	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—CHRM3—nephrolithiasis	0.000384	0.00261	CbGpPWpGaD
Metoprolol—ADRB1—Signaling by GPCR—PTH—nephrolithiasis	0.000359	0.00244	CbGpPWpGaD
Metoprolol—ADRB2—Signaling by GPCR—PTH—nephrolithiasis	0.000351	0.00238	CbGpPWpGaD
Metoprolol—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000341	0.00231	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000321	0.00218	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—DGKH—nephrolithiasis	0.000321	0.00218	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—DGKH—nephrolithiasis	0.000314	0.00213	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000314	0.00213	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—GRHPR—nephrolithiasis	0.000303	0.00205	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—GRHPR—nephrolithiasis	0.000295	0.002	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—AQP1—nephrolithiasis	0.000292	0.00198	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—GRHPR—nephrolithiasis	0.000278	0.00189	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—AGXT—nephrolithiasis	0.00027	0.00183	CbGpPWpGaD
Metoprolol—SLC22A2—Metabolism—CHRM3—nephrolithiasis	0.000264	0.00179	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—AGXT—nephrolithiasis	0.000263	0.00179	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—AGXT—nephrolithiasis	0.000248	0.00168	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—CHRM3—nephrolithiasis	0.000232	0.00157	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—SLC26A1—nephrolithiasis	0.000229	0.00156	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—APRT—nephrolithiasis	0.000229	0.00156	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—CHRM3—nephrolithiasis	0.000227	0.00154	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—SLC26A1—nephrolithiasis	0.000224	0.00152	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—APRT—nephrolithiasis	0.000224	0.00152	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—PTH—nephrolithiasis	0.000212	0.00144	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	0.000211	0.00143	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—APRT—nephrolithiasis	0.000211	0.00143	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—PTH—nephrolithiasis	0.000208	0.00141	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—AQP1—nephrolithiasis	0.000163	0.00111	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—AQP1—nephrolithiasis	0.00016	0.00108	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—AQP1—nephrolithiasis	0.00015	0.00102	CbGpPWpGaD
Metoprolol—CYP2C19—Metabolism—CHRM3—nephrolithiasis	0.000148	0.001	CbGpPWpGaD
Metoprolol—ABCB1—Metabolism—CHRM3—nephrolithiasis	0.000144	0.000978	CbGpPWpGaD
Metoprolol—CYP2D6—Metabolism—CHRM3—nephrolithiasis	0.000136	0.000922	CbGpPWpGaD
Metoprolol—ADRB1—Signaling Pathways—SPP1—nephrolithiasis	0.000107	0.000722	CbGpPWpGaD
Metoprolol—ADRB2—Signaling Pathways—SPP1—nephrolithiasis	0.000104	0.000707	CbGpPWpGaD
